Chapter 5. Discovery of Motesanib

  1. Rongshi Li and
  2. Jeffrey A. Stafford
  1. Andrew S. Tasker1 and
  2. Vinod F. Patel2

Published Online: 28 SEP 2009

DOI: 10.1002/9780470524961.ch5

Kinase Inhibitor Drugs

Kinase Inhibitor Drugs

How to Cite

Tasker, A. S. and Patel, V. F. (2009) Discovery of Motesanib, in Kinase Inhibitor Drugs (eds R. Li and J. A. Stafford), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470524961.ch5

Editor Information

  1. Takeda San Diego, Inc., San Diego, CA 92121, USA

Author Information

  1. 1

    Chemistry Research and Discovery, Amgen, Inc., Thousand Oaks, CA 91320, USA

  2. 2

    Chemistry Research and Discovery, Amgen, Inc., Cambridge, MA 02139, USA

Publication History

  1. Published Online: 28 SEP 2009
  2. Published Print: 2 OCT 2009

Book Series:

  1. Wiley Series in Drug Discovery and Development

Book Series Editors:

  1. Binghe Wang

ISBN Information

Print ISBN: 9780470278291

Online ISBN: 9780470524961

SEARCH

Keywords:

  • discovery of motesanib;
  • lead optimization strategy;
  • motesanib and assessing activity along VEGF–VEGFR signaling pathway

Summary

This chapter contains sections titled:

  • Introduction

  • Background and Lead Optimization Strategy

  • Pharmacology

  • Summary

  • Acknowledgments

  • References